Zealand Pharma SG&A Expenses 2017-2024 | ZLDPF

Zealand Pharma sg&a expenses for the twelve months ending September 30, 2024 were $0.046B, a 97.63% increase year-over-year.

  • Zealand Pharma annual sg&a expenses for 2023 were $0.031B, a 17.84% decline from 2022.
  • Zealand Pharma annual sg&a expenses for 2022 were $0.038B, a 62.3% decline from 2021.
  • Zealand Pharma annual sg&a expenses for 2021 were $0.101B, a 35.39% increase from 2020.

Zealand Pharma SG&A Expenses 2017-2024 | ZLDPF

  • Zealand Pharma annual sg&a expenses for 2023 were $0.031B, a 17.84% decline from 2022.
  • Zealand Pharma annual sg&a expenses for 2022 were $0.038B, a 62.3% decline from 2021.
  • Zealand Pharma annual sg&a expenses for 2021 were $0.101B, a 35.39% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$146.3B
Gilead Sciences (GILD)$114.5B
Bristol Myers Squibb (BMY)$114.2B
Vertex Pharmaceuticals (VRTX)$108.7B
CSL (CSLLY)$83.4B
Regeneron Pharmaceuticals (REGN)$74.9B
GSK (GSK)$69.3B
Argenex SE (ARGX)$38.7B
Alnylam Pharmaceuticals (ALNY)$31.8B
BioNTech SE (BNTX)$26.8B
Illumina (ILMN)$21.7B
BeiGene (ONC)$20.5B
Biogen (BIIB)$20.5B
Incyte (INCY)$13.9B
Genmab (GMAB)$13.8B
Genmab (GNMSF)$13.7B
Intra-Cellular Therapies (ITCI)$13.4B
Moderna (MRNA)$13.1B
Insmed (INSM)$13B
Bio-Techne Corp (TECH)$12B
BioMarin Pharmaceutical (BMRN)$11.7B
Sarepta Therapeutics (SRPT)$11.3B
Vaxcyte (PCVX)$10.6B
QIAGEN (QGEN)$10.5B
Exelixis (EXEL)$10.3B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Exact Sciences (EXAS)$9.6B
Bio-Rad Laboratories (BIO.B)$9.5B
Repligen (RGEN)$9B
Roivant Sciences (ROIV)$8.1B